| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/11/2009 | WO2009109493A2 2-aminoquinolines |
| 09/11/2009 | WO2009109491A1 2-aminoquinoline derivatives |
| 09/11/2009 | WO2009109477A1 2-aminoquinolines |
| 09/11/2009 | WO2009109401A1 Salts of memantine and cox-inhibitors and their crystalform in the treatment of pain |
| 09/11/2009 | WO2009109334A1 (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| 09/11/2009 | WO2009109230A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 09/11/2009 | WO2009109001A1 Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function |
| 09/11/2009 | WO2009108999A1 Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| 09/11/2009 | WO2009089635A9 Treating neurodegenerative diseases with progranulin (pgrn) |
| 09/11/2009 | WO2009040069A3 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 09/11/2009 | WO2009033821A3 Use of a peptide as a therapeutic agent |
| 09/11/2009 | WO2009033779A3 Nociceptin for use as a therapeutic agent |
| 09/11/2009 | WO2009033778A3 Mage-3 antigen and others for use as a therapeutic agent |
| 09/11/2009 | WO2009033775A3 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent |
| 09/11/2009 | WO2009033732A3 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent |
| 09/11/2009 | WO2009033729A3 Therapeutic uses of gastrin- 1 and g- pen-grgdspca |
| 09/11/2009 | WO2009030065A8 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| 09/11/2009 | WO2007130927A3 Condensed tricyclic compounds as cgrp-receptor antagonists |
| 09/11/2009 | CA2719115A1 Methods, dosage forms, and kits for administering ziprasidone without food |
| 09/11/2009 | CA2717478A1 Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof |
| 09/11/2009 | CA2717453A1 2-aminoquinolines |
| 09/11/2009 | CA2717172A1 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
| 09/11/2009 | CA2717171A1 Amino-quinoxaline and amino-quinoline compounds for use as adenosine a2a receptor antagonists |
| 09/11/2009 | CA2716863A1 Sub-type selective amides of diazabicycloalkanes |
| 09/11/2009 | CA2716799A1 Methods of treating inflammatory pain |
| 09/11/2009 | CA2716424A1 Methods of treating chronic pain |
| 09/11/2009 | CA2716354A1 Contrast agents for applications including perfusion imaging |
| 09/11/2009 | CA2716122A1 2-aminoquinolines |
| 09/11/2009 | CA2715842A1 2-aminoquinoline derivatives |
| 09/11/2009 | CA2715796A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 09/11/2009 | CA2712921A1 Derivatives of indole 2-carboxamides and azaindole 2-carboxamides substituted by a silanyle group, preparation thereof and therapeutic use thereof |
| 09/11/2009 | CA2712703A1 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 09/11/2009 | CA2712403A1 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 09/11/2009 | CA2711247A1 2-aminoquinolines |
| 09/10/2009 | US20090228997 Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |
| 09/10/2009 | US20090227768 Anti-Allergic Complex Molecules |
| 09/10/2009 | US20090227686 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 09/10/2009 | US20090227682 Xetine compositions |
| 09/10/2009 | US20090227673 Method and Composition for the Treatment of Parkinson's Disease |
| 09/10/2009 | US20090227667 5'-chloro-N-[3,3,3-trifluoro-2-(trifluoromethyl)-1S-(hydroxymethyl)propyl]thiophene-2'-sulfonamide, used for the treatment of Alzheimer's Disease and Down's syndrome |
| 09/10/2009 | US20090227656 Methods for using modulators of proline-rich tyrosine kinase 2 |
| 09/10/2009 | US20090227655 Nonviral vectors for delivering polynucleotides to target tissue |
| 09/10/2009 | US20090227644 Agent for regeneration and/or protection of nerves |
| 09/10/2009 | US20090227642 Novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| 09/10/2009 | US20090227632 Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin reuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| 09/10/2009 | US20090227628 2-aminoquinolines |
| 09/10/2009 | US20090227627 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
| 09/10/2009 | US20090227615 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
| 09/10/2009 | US20090227614 Modulators of Muscarinic Receptors |
| 09/10/2009 | US20090227613 Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors |
| 09/10/2009 | US20090227605 Enhanced efficacy benzisoxazole derivative dosage forms and methods |
| 09/10/2009 | US20090227595 Glycine transporter-1 inhibitors |
| 09/10/2009 | US20090227593 Cyclobutyl amine derivatives |
| 09/10/2009 | US20090227589 Pyrazole derivatives as sigma receptors antagonists |
| 09/10/2009 | US20090227584 2-aminoquinoline derivatives |
| 09/10/2009 | US20090227583 2-aminoquinolines |
| 09/10/2009 | US20090227582 Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| 09/10/2009 | US20090227577 Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer |
| 09/10/2009 | US20090227570 2-aminoquinolines |
| 09/10/2009 | US20090227567 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 09/10/2009 | US20090227562 Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| 09/10/2009 | US20090227558 Amino-derivatives as novel inhibitors of histone deacetylase |
| 09/10/2009 | US20090227551 Therapeutic Uses of Steroidal Compounds |
| 09/10/2009 | US20090227550 Controlled release delivery system for nasal application of neurotransmitters |
| 09/10/2009 | US20090227534 Pharmaceutical Composition Comprising the Combination of a Ketorolac Salt and Vitamins of the-B-Complex for the Treatment of Neuralgia |
| 09/10/2009 | US20090227523 Use of compatible solutes as substances having free radical scavenging properties |
| 09/10/2009 | US20090227522 Targeted Delivery of Pharmaceutical Compounds |
| 09/10/2009 | US20090227521 Use of compounds in the treatment of ischemia and neurodegeneration |
| 09/10/2009 | US20090227520 Treatment methods using peptides related to amyloid precursor protein |
| 09/10/2009 | US20090227492 TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS |
| 09/10/2009 | US20090226987 Desaturase Genes, Enzymes Encoded Thereby, and Uses Thereof |
| 09/10/2009 | US20090226536 Methods and materials relating to enhanced production of dopamine neurons |
| 09/10/2009 | US20090226528 Encapsulated nanoparticles for nucleic acid delivery |
| 09/10/2009 | US20090226517 Pharmaceutical formulations comprising duloxetine |
| 09/10/2009 | US20090226510 Pharmaceutical compositions of atorvastatin |
| 09/10/2009 | US20090226482 Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same |
| 09/10/2009 | US20090226481 Compositions Ameliorating a Reduced Diurnal Activity and/or Depressive Symptoms |
| 09/10/2009 | US20090226468 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS |
| 09/10/2009 | US20090226439 Method for treating dementia or alzheimer's disease |
| 09/10/2009 | US20090226436 Novel receptors |
| 09/10/2009 | US20090226403 Olfactory and pheromones G-protein coupled receptors |
| 09/10/2009 | DE102009011742A1 Aqueous liquid formulation, useful for treating migraine, comprises phospholipids, coenzyme Q10, blueberry extract (extract of Vaccinium myrtillus), and polyol comprising e.g. aldose, ketose, reduced aldose and/or ketose |
| 09/10/2009 | DE102008003467A1 Flavonoide als Mittel zur Prophylaxe und Behandlung von neurodegenerativen und anderen Proteinfehlfaltungskrankheiten Flavonoids as a means for the prophylaxis and treatment of neurodegenerative diseases and other protein misfolding |
| 09/09/2009 | EP2098526A1 Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| 09/09/2009 | EP2098513A1 Tricyclic compound and pharmaceutical use thereof |
| 09/09/2009 | EP2098509A1 1-naphthyl alkylpiperidine derivative |
| 09/09/2009 | EP2098500A1 Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain |
| 09/09/2009 | EP2098248A1 Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases |
| 09/09/2009 | EP2098245A1 Use of cholinesterase for manufacturing an anti-tachykinins medicament |
| 09/09/2009 | EP2098237A1 Analgesic agent comprising cyclic phosphatidic acid derivative |
| 09/09/2009 | EP2098235A1 Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation |
| 09/09/2009 | EP2098234A1 Skin adhesive preparation comprising stabilized donepezil |
| 09/09/2009 | EP2098233A1 Skin adhesive preparation comprising stabilized donepezil |
| 09/09/2009 | EP2098232A1 Percutaneous absorption preparation |
| 09/09/2009 | EP2098229A1 Nerve regeneration agent |
| 09/09/2009 | EP2097437A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| 09/09/2009 | EP2097415A1 8-ethinylxanthine derivatives as selective a2a receptor antagonists |
| 09/09/2009 | EP2097409A1 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhbitors |
| 09/09/2009 | EP2097394A1 1,2,4-triazole derivatives as sigma receptor inhibitors |
| 09/09/2009 | EP2097392A1 1,2,3-triazole derivatives as sigma receptor inhibitors |